High affinity human antibodies to PCSK9
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. Sleeman, Joel H. Martin, Tammy T Huang, Douglas MacDonald
Life of this patent
Estimating the term…
Abstract
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Claims3
An antibody or antigen binding fragment of an antibody that specifically binds hPCSK9, comprising heavy and light chain CDR sequences from the HCVR and LCVR sequence pair having SEQ ID NOs:
- 90/92.
Dependencies are inferred from the claim text.